Table 1.
Demographic and clinical characteristics and medications targeting bone and mineral disorders in 100 ESRD patients undergoing living donor kidney transplantation, grouped according to primary kidney disease (i.e., autosomal polycystic kidney disease, versus other primary kidney diseases)
| ADPKD (n = 19) |
CGN (n = 38) |
DM (n = 7) |
Other (n = 36) |
P value | |
|---|---|---|---|---|---|
| Age (yr) | 56 (43–66) | 37 (23–63) | 53 (45–61) | 44 (23–64) | 0.0008 |
| Male gender (%) | 58 | 58 | 57 | 69 | 0.72 |
| DM (not as primary cause of ESRD) (%) | 26 | 14 | N/A | 6 | 0.08 |
| Cardiovascular disease (%) | 21 | 8 | 71 | 17 | 0.0048 |
| Dialysis vintage (yr) | 0.5 | 1.0 | 3.1 | 1.0 | 0.002 |
| Preemptive RTx (%) | 16 | 49 | 3 | 32 | 0.18 |
| Body mass index (kg/m2) | 24.5 (21.3–29.3) | 24.3 (19.7–28.8) | 25.4 (19.8–27.8) | 23.4 (19.8–27.2) | 0.72 |
| Creatinine (μmol/l) | 683 (569–924) | 732 (465–1047) | 644 (490–1014) | 785 (421–1153) | 0.84 |
| hs C-reactive protein (mg/l) | 1.1 (0.2–14.6) | 0.8 (0.2–3.9) | 1.5 (0.6–11.4) | 0.7 (0.2–6.0) | 0.23 |
| IL–6 (pg/ml) | 1.34 (0.01–10.95) | 0.98 (0.01–2.76) | 1.78 (0.95–21.43) | 0.87 (0.01–3.06) | 0.068 |
| Albumin (g/l) | 37 (31–42) | 35 (32–42) | 36 (31–39) | 36 (33–39) | 0.94 |
| Ca-containing phosphate binders (% treated) | 68 | 61 | 71 | 36 | 0.049 |
| Ca-free phosphate binders (% treated) | 58 | 79 | 71 | 75 | 0.42 |
| Vitamin D3 supplements (% treated) | 0 | 3 | 14 | 3 | 0.42 |
| Active vitamin D supplements (% treated) | 95 | 90 | 71 | 75 | 0.14 |
| Cinacalcet (% treated) | 11 | 11 | 43 | 11 | 0.24 |
| ESA (% treated) | 89 | 79 | 57 | 75 | 0.33 |
| Iron (% treated) | 74 | 35 | 57 | 50 | 0.20 |
| Statin (% treated) | 37 | 26 | 57 | 25 | 0.31 |
| ACEI/ARB (% treated) | 58 | 66 | 29 | 53 | 0.28 |
| Ca channel blocker (% treated) | 47 | 53 | 14 | 50 | 0.27 |
Significant differences are indicated in bold.
ACEI, angiotensin-converting enzyme inhibitor; ADPKD, autosomal dominant polycystic kidney disease; ARB, angiotensin receptor blocker; Ca, calcium; CGN, glomerulonephritis; D3, cholecalciferol; DM, diabetes mellitus; ESA, erythropoietin-stimulating agent; ESRD, end-stage renal disease; hs, high-sensitivity; IL, interleukin; RTx, renal transplantation.